Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s): ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

TSX:ATE - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dr. John Wallace

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Sep 09, 2020 3:48pm

143 Views

Post# 31528062

RE:RE:RE:Dr. John Wallace

Hey Marky. whats going on man? I saw some of your comments on CEO. You getting cold feet. Your faith seems to have shaken a bit haha.\

Marky1 wrote:
Which discussion are you referring to?? I've been in this company since August 2019 when Bob McWhirter chose it a top pick.

My shares are stored away in my vault of hopes and wishes..

everyone out there...We have a winner, we have the greatest drug invention since Acetaminophen ( not an NSAID ) The market cap should, and will be, as said in the BioPub, 600M$ USD which works out to be $2 a share CDN....
Patience is a virtue and a necessary state of mind here..